Zenodo (CERN European Organization for Nuclear Research)
March 20, 2026
Irmak Çankaya
preprint
Contemporary psychiatry primarily utilizes biomedical models that categorize mental disorders through observable symptoms, which risks overlooking how these experiences are actually lived by individuals. This article examines melancholic depression through the lens of phenomenological psychopathology, arguing that it represents a radical, structural transformation of the subject’s...
International Journal of Molecular Sciences
March 20, 2026
Ana Zivanovic, Milos Mitic, Iva Lukic et al.
Major depressive disorder (MDD) is a highly prevalent psychiatric illness for which rapid-acting antidepressants such as ketamine provide only transient benefit. Because κ-opioid receptor (KOR) signaling contributes to stress-related dysphoria and impaired neuroplasticity, we examined whether KOR antagonism could prolong ketamine’s antidepressant-like effects in a mouse model of adolescent...
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
March 20, 2026
Zhuoning Zhang, Xinyu Hao, Fuyang Cao et al.
To investigate the regulatory role of glutamatergic neurons in the medial prefrontal cortex (mPFC) in the antidepressant effects of esketamine. A total of 150 male C57BL/6J mice were randomly divided into 15 groups (n=10). The mice subjected to the chronic restraint stress (CRS), and those exhibiting depressive-like behaviors following CRS received either esketamine or saline treatment, and...
International Journal of Innovative Technologies in Social Science
March 19, 2026
Anna Komarczewska, Michał Kociński, Patryk Iglewski et al.
Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocybin-assisted therapy has recently...
The Journal of ECT
March 19, 2026
Jennifer Sjödin, Karin Zimmer, Max Bell et al.
Electroconvulsive therapy (ECT) is an established treatment of major depressive disorder (MDD), particularly in severe cases and in cases resistant to pharmacological interventions. Anesthesia plays an important role in optimizing patient tolerability during ECT but may attenuate the treatment effect, as anesthetic agents elevate the seizure threshold. This review aims to examine the impact of...
JAMA Psychiatry
March 18, 2026
Zachary J. Williams, Hannah Barnett, Balázs Szigeti
10 citations
Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions. Because PAT is effectively always open label, treatment results should be compared with those of open-label traditional antidepressants (TADs), so potential benefits associated with patients knowing their treatment is equal between...
JAMA Psychiatry
March 18, 2026
Lea J. Mertens, Michael Koslowski, Felix Betzler et al.
9 citations
Importance: Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. Objective: To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD). Design, Setting, and Participants: This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active...
BMC Psychiatry
March 17, 2026
Bernhard T Baune, Kevin Rosemann, Dimitri Hefter et al.
2 citations
BACKGROUND: Intranasal esketamine has recently emerged as an innovative treatment option for treatment-resistant depression (TRD). This retrospective, uncontrolled study aimed to evaluate the real-world effectiveness of esketamine in an naturalistic inpatient setting and explore demographic and clinical factors associated with treatment response. METHODS: We conducted a chart review of 101...
Psychopharmacology
March 16, 2026
Ye Li, Qilong Cheng, Guoxin Lin et al.
RATIONALE: Major Depressive Disorder (MDD) is a global public health burden, with traditional monoaminergic antidepressants facing critical limitations including slow onset, adverse side effects, and high rates of treatment resistance (TRD). Ketamine, a rapid-acting agent with sustained antidepressant effects, has revolutionized depression treatment paradigms but challenges conventional...
Frontiers in Computer Science
March 16, 2026
Akey Sungheetha, R. Rajesh Sharma, Oluwasegun Julius Aroba et al.
Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, not from real-time clinical...
Behaviour Research and Therapy
March 15, 2026
Ying Huang, Z. Chong, Zenan Dou et al.
OBJECTIVES This study evaluated the comparative efficacy of a self-help mindfulness intervention (sMBI) and a combined mindfulness and cognitive behavioral therapy intervention (sMBI + CBT) in reducing symptoms of depression and anxiety. Additionally, it explored the mechanisms underlying these interventions. METHODS In this randomized controlled trial (RCT), 335 university students from...
Journal of Affective Disorders
March 15, 2026
Patrícia Cavalcanti-Ribeiro, Lara Carvalho Araújo Melo De Souza, Vagner Deuel O de Tavares et al.
Treatment-resistant depression (TRD) remains a major clinical challenge, with inflammation increasingly implicated in its pathophysiology. C-reactive protein (CRP), an accessible biomarker, has emerged as a potential predictor of antidepressant response. While intravenous and intranasal ketamine have shown anti-inflammatory effects, evidence linking inflammation and clinical outcomes remains...
Cureus
March 14, 2026
Suneha Shelke, Rusheeth Thummalapally
Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other compulsive behaviors. With up to a third of major depressive disorder (MDD) patients failing to respond to standard antidepressant therapies, there is growing interest in interventions such as esketamine, a glutamatergic N-methyl-D-aspartate (NMDA)...
Clinics and practice
March 13, 2026
Alessandro Guffanti, Matteo Leonardi, Natascia Brondino et al.
Major depressive disorder (MDD) is a leading cause of disability worldwide and contributes significantly to the global burden of disease. Recent data show an increasing prevalence of treatment-resistant depression (TRD). Patients with autism spectrum disorder (ASD) often exhibit MDD as a comorbidity and it is often resistant to conventional treatments. ASD determines emotional dysregulation and...
Audiology & neuro-otology
March 12, 2026
Weronika Caban, Paweł Holas, Mikołaj Kuncewicz et al.
Introduction: Tinnitus is the perception of sound in the absence of external stimuli, often experienced as ringing or buzzing. While many individuals habituate to tinnitus, others develop chronic tinnitus (CT), which can severely affect emotional well-being. Psychological mechanisms such as anxiety and maladaptive coping are known contributors to tinnitus distress, yet the protective role of...
arXiv Preprint Archive
March 12, 2026
Yuxin Zhu, Sahithi Lakamana, Masoud Rouhizadeh et al.
preprint
Treatment-resistant depression (TRD) is a severe form of major depressive disorder in which patients do not achieve remission despite multiple adequate treatment trials. Evidence across pharmacologic options for TRD remains limited, and trials often do not fully capture patient-reported tolerability. Large-scale online peer-support narratives therefore offer a complementary lens on how patients...
Journal of Innovative and Creativity
March 11, 2026
Agriefa Chrysantia Noormay El Kariim, Novia Tria Nurcahya, Almira Clarissa Sungkono et al.
Background: Cancer patients often experience significant emotional burdens due to the diagnosis, treatment process, and uncertainty regarding their prognosis. Psilocybin, a psychedelic compound found in certain mushroom species, has gained increasing attention in mental health research for its potential therapeutic effects in treating depression and anxiety. Methods: This systematic review...
International Journal of Psychiatry in Clinical Practice
March 11, 2026
Michele Prato, Matteo Carminati, Filippo Frizzi et al.
1 citation
Background: Treatment-Resistant Depression (TRD) often persists despite adequate pharmacotherapy. Intranasal Esketamine and accelerated repetitive Transcranial Magnetic Stimulation (aTMS) are rapid-acting options, but head-to-head comparisons remain limited. Methods: We conducted a retrospective study on TRD patients receiving either aTMS (n = 18) or Intranasal Esketamine (n = 22). Depression...
Pharmacological Reports
March 11, 2026
Benjamin D. Brody, Dora Kanellopoulos
1 citation
Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and...
Cambridge Prisms Global Mental Health
March 10, 2026
Jiawei Wang, Yechen Wu, Fan Yang et al.
Coronary heart disease (CHD) often coexists with mood disorders (MDs), but research on comorbidity predictors and interventions remains limited. This two‑phase mixed‑methods study enrolled 390 CHD patients diagnosed by coronary angiography. Mood disorders were screened using the HAMD (≥7) and confirmed via DSM‑5 psychiatric evaluation. In the observational phase, 219 CHD patients with MDs and...